Viral etiology of life-threatening pediatric pneumonia: A matched case-control study

Jianxing Yu1 | Suyun Qian2 | Chunyan Liu2 | Yan Xiao1 | Teng Xu3 | Ying Wang1 | Hang Su4 | Lan Chen1 | Bin Yuan4 | Xinming Wang1 | Baoping Xu2 | Yan Yang2 | Kunling Shen2 | Zhengde Xie2 | Lili Ren1 | Jianwei Wang1

1National Health Commission Key Laboratory of Systems Biology of Pathogens and Christophe Merieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
2Beijing Key Laboratory of Pediatric Respiratory Infection Diseases, Key Laboratory of Major Diseases in Children, Ministry of Education, National Clinical Research Center for Respiratory Diseases, National Key Discipline of Pediatrics (Capital Medical University), Beijing Pediatric Research Institute, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing, China
3Vision Medicals, Guangzhou, China
4The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

Abstract

Background: Pediatric pneumonia remains a significant health challenge, while the viral risk factors for adverse outcomes in pediatric pneumonia are not yet fully clear.

Methods: A matched case-control study of pediatric patients with pneumonia was carried out in Beijing, China, between 2007 and 2015. The study enrolled 334 intensive care unit patients who developed life-threatening diseases and 522 controls matched to the sex, age, ethnicity, admission dates, and residing district of the cases suffered from pneumonia. Nasopharyngeal aspirates were taken from all participants and tested by PCR for 18 common respiratory viruses.

Results: At least, one virus was detected in 257 (77%) of the cases and 409 (78%) of the controls. We observed no difference in the prevalence of 17 respiratory viruses between cases and controls but found a higher frequency of influenza A virus (IFV-A) in the cases than in the controls (7% vs 4%, \( P = .036 \)). After adjusting for comorbid conditions and a history of reactive airway diseases, IFV-A was associated with an increase in life-threatening pneumonia (adjusted odds ratio = 2.55, 95% CI = 1.24-5.24). Young age and congenital heart disease (aOR = 10.16-10.27, \( P < .001 \)) were also independent risk factors.

Conclusions: The prevention of IFV infection is critical in decreasing the risk of life-threatening pneumonia in children.
1 | INTRODUCTION

Pneumonia is a leading cause of death globally, particularly for children. One in five children worldwide suffers an episode of pneumonia each year, and 12%-25% of pediatric pneumonia patients progress to severe pneumonia requiring hospital referral and treatment. Roughly 21% of children who require hospitalization for pneumonia are admitted into a pediatric intensive care unit (PICU), resulting in death in as many as 1% of cases. Due to the health burden of pediatric pneumonia, there is a growing interest in clarifying the etiological agents that contribute to the severity and progression of the disease, and respiratory viruses have been explored in this context.

The respiratory viruses associated with the incidence of pneumonia have been reported. However, few data described the contributions of viral agents to the development of severe pneumonia among children in inpatient settings. The understanding of the risk factors that predispose pediatric pneumonia patients to life-threatening events may help improve clinical care, guide diagnostic testing, reduce the number of unnecessary antibiotic prescriptions, decrease medical costs, and lower the risk of nosocomial infections in a hospital setting.

To clarify the contributions of respiratory viruses to very severe pediatric pneumonia, we conducted a matched case-control study to assess the contributions of several common respiratory viruses.

2 | MATERIALS AND METHODS

2.1 | Study design

A matched case-control study was designed to analyze a cohort of pediatric patients with pneumonia at Beijing Children’s Hospital from April 1, 2007, to December 31, 2015, in Beijing, China. The following three criteria were used to enroll patients: (a) had symptoms of acute infection, including fever (body temperature >38.0°C) or hypothermia (body temperature <35.5°C), leukocytosis (for children <5 years old, white blood cell count [WBC] >15 000/mL, and for children ≥5 years old, WBC >11 000/mL), or leukopenia (for children <5 years old, WBC <5000/mL, and for children ≥5 years old, WBC <4000/mL); (b) had signs and/or symptoms of lower respiratory tract infections, including cough, sputum production, shortness of breath, tachypnea (based on age: <2 months, ≥60 breaths/min; 2-11 months, ≥50 breaths/min; 12-59 months, ≥40 breaths/min; ≥5 years, ≥30 breaths/min), wheezing or crackles, dyspnea, or chest pain; and (c) had radiograph evidence suggestive of pneumonia or pleural effusion. Patients were excluded if they were younger than 28 days or older than 14 years of age, with known immunosuppressive diseases including solid organ or hematopoietic stem cell transplants, receiving chemotherapy, HIV-positive or had AIDS, and taking steroids for more than 30 days. To avoid duplication, patients who had recurrent hospitalizations within 3 months of enrollment were also excluded.

Nasopharyngeal aspirates were collected from each enrolled patient. Nucleic acids were extracted from the aspirates and screened for the presence of 18 respiratory viruses using reverse transcriptase-polymerase chain reaction (RT-PCR) and PCR assays as described previously. The viral agents screened included influenza viruses (IFV-A, -B, and -C), human rhinovirus (HRV), human parainfluenza virus 1-4 (HPIV-1, -2, -3, and -4), respiratory syncytial virus (RSV-A and -B), human adenovirus (Adv), enterovirus (EV), human bocavirus (HBoV), human metapneumovirus (HMPV), and human coronavirus (HCoV-229E, OC43, NL63, and HKU1). We did not perform IFV-A subtyping assays in the study.

All hospitalized patients were reviewed retrospectively to determine the assignment of cases and controls. All patients who were admitted into the PICU and developed life-threatening diseases, defined as mechanical ventilation, sepsis, shock, or death, were defined as cases. These patients ranged in ages from 28 days to 13 years. Control patients were selected from general wards and did not present with life-threatening diseases. For each case, up to two controls were matched according to sex, age (±2 months), ethnicity, admission date (±15 days), and residing district. If no eligible controls were found, the matched conditions were expanded to include patient ±6 months of age and with an admission date of ±4 weeks for patients <5 years of age, or age of ±1 years and an admission date of ±4 weeks in patients more than 5 years of age. Two controls were selected at random if there were more than two eligible controls in the cohort.

To validate the data, two pediatricians and one pediatric radiologist independently reviewed all chest radiographs, important clinical outcomes, and diagnoses. Inconsistent diagnoses were discussed with a third senior pediatrician, who would make a final decision. Clinical outcomes or diagnoses used to define the cases and controls were collected from medical charts at the time of hospital discharge, including PICU admission, non-invasive ventilation, for example, continuous positive airway pressure (CPAP), invasive ventilation including mechanical ventilation involving tracheostomy or endotracheal tube, acute respiratory failure (code 518.81) according to the International Classification of Diseases, ninth revision (ICD-9), shock (ICD-9 code 785.5x), sepsis (ICD-9 code 038.xx), and death. Baseline data at hospital admission, including demographic data (sex and age), epidemiological data (date of illness onset and prematurity history of children defined as gestational age of children <37 weeks), and clinical data (symptoms/signs and comorbid conditions) were retrieved from study records. Observed comorbid conditions included congenital heart disease (CHD), defined as children with a diagnosis ICD-9 coded as 745.
xx, 746.xx, and 747.xx, chronic lung disease, chromosomal anomalies, moderate-to-severe anemia (haemoglobin <90 g/L), and malnutrition.

The study was approved by the ethical review committee at the Institute of Pathogen Biology, Chinese Academy of Medical Sciences [IPB, Beijing, China [ref. IPB-2014-4]]. Written consent was obtained before enrollment from each patient or their guardians.

2.2 | Statistical analysis

We used chi-square tests or Fisher's exact tests to analyze categorical variables and Wilcoxon rank-sum tests to analyze continuous variables as appropriate. A two-sided P-value of < .05 was considered statistically significant. Conditional logistic regression was used to explore the relationship between viral exposure at hospital admission and subsequent life-threatening disease during hospitalization. The comorbidities, breast-feeding, influenza vaccination last year, and initial antibiotic usage were also included in the multivariable conditional logistic regression to account for potential confounders if they were significant at P < .10 in univariate analysis. Data are reported as crude or adjusted odds ratio (OR) with a 95% confidence interval (95% CI). We also conducted sensitive analysis between different age strata, for example, children aged 1-59 months and children 5-13 years. All analyses were conducted in R version 2.15.3 (R Foundation for Statistical Computing).10

3 | RESULTS

3.1 | Characteristics of subjects

During the study period, a total of 4568 pediatric patients were hospitalized for pneumonia. We identified 347 (8%) PICU admissions with life-threatening events during hospitalization, of which 13 cases were excluded because no eligible matched controls were available, even using the expanding matched criteria (Figure 1). A total of 334 cases and 522 matched controls were included in our analysis, for which 188 (56%) had two matched controls and 146 (44%) had one matched control. Demographic and vaccination information as well as descriptions of the underlying disease are provided in Table 1. The median age of the cases was 6 months, and 49% (n = 162) of PICU admissions were for children younger than 6 months. The frequency of congenital heart diseases was higher in the cases than in the controls (38% vs 8%, P < .001, Fisher's exact test). The rate of antibiotic usage (93% vs 99%, P < .001, Fisher's exact test) and the prevalence of a history of asthma and other reactive airway diseases (2% vs 5%, P < .024, Fisher's exact test) were lower in the cases than in the controls. The rate of influenza vaccination in the past year was not statistically different in the cases and the controls (14% vs 14%, P = .841, Fisher's exact test) (Table 1). All patients in both group had no history of anti-viral drugs treatment before seeing a doctor.

3.2 | Association between respiratory viruses and life-threatening events

At least, one virus was detected in 257 (77%) cases and in 409 (78%) controls. The species and subtypes of respiratory virus detected in the cases and controls are listed in Table 2. In both the cases and the controls, the detection rates of the respiratory viruses were RSV (38%, 46%), HRV (23%, 23%), HPIV (17%, 19%), HBoV (11%, 9%), Adv (7%, 9%), hMPV (4%, 5%), HCoV (4%, 3%), and EVs (3%, 2%) (Figure 2). Among all the detected viruses, only the frequency of IFV-A virus was greater in the cases than in the controls (7% vs 4%, P = .036; Fisher's exact test), while the other respiratory viruses showed no significant difference between the two groups.

To clarify the contributions of viruses to life-threatening disease, we analyzed the associations between each virus and an adverse clinical record. IFV-A was analyzed firstly as its higher frequency in the cases. Univariate analysis revealed that IFV-A was significantly associated with an increased frequency of life-threatening events (OR = 2.55, 95% CI = 1.24-5.24). This association persisted (adjusted odds ratio (aOR) =2.52, 95% CI = 1.15-5.55) after adjusting for potential confounders, including comorbidities, antibiotic usage, and a history of other reactive airway diseases. Although RSV was the most detected viruses in the two groups, however, RSV-positive detection was negatively associated with the life-threatening events (OR = 0.68, 95% CI = 0.48-0.94). After controlling for confounding variables, we did not observe an association between RSV and the occurrence of life-threatening events (aOR = 0.75, 95% CI = 0.51-1.10). Sensitive analysis showed similar results in children aged 1-59 months (Table S1). In adjusted models for RSV infection or IFV-A infection, congenital heart disease (aOR = 10.16 [95% CI = 5.94-17.37] for RSV and aOR = 10.27 [95% CI = 6.06-17.75] for IFV-A) was strongly associated with an increased frequency of life-threatening pneumonia.

We also analyzed the codetection rates of respiratory viruses, but observed no significant difference in the cases (97, 29%) and controls (175, 34%) (P = .241, Fisher's exact test) (Table 2). RSV with HRV were in highest codetection frequency in both cases (n = 24, 7%) and controls (n = 45, 9%).

3.3 | Clinical signs and outcomes in relation to viral findings

We then analyzed the relationships between clinical symptoms, prognosis, and the tested respiratory viruses. Although only 42 children were IFV-A-positive, these patients had higher rates of pediatric PICU admission (55% vs 38%, P = .036), invasive ventilation
YU et al. (36% vs 10%, $P < .001$), and acute respiratory failure (45% vs 29%, $P = .024$) than did the IFV-A negative patients with Fisher's exact test. Fever $> 38.5^\circ C$ (63% vs 40%, $P = .005$) and tachycardia (60% vs 41%, $P = .024$) were positively associated with IFV-A positive detections with Fisher's exact test (Table 3).

RSV was the most frequently detected virus in hospitalized patients, but RSV-positive patients were less likely to develop life-threatening disease, as evidenced by lower rates of pediatric PICU admission (35% vs 42%, $P = .028$), invasive ventilation (7% vs 14%, $P < .001$), shock (0% vs 3%, $P = .006$), sepsis (2% vs 5%, $P = .045$), and death (0% vs 2%, $P = .012$), compared to children tested negative for RSV with Fisher's exact test. Fever $> 38.5^\circ C$ (26% vs 52%, $P < .001$) was observed less frequently in RSV-positive patients, but chest indrawing (53% vs 35%, $P < .001$) was more frequent in RSV-positive patients compared to RSV-negative subjects (Table S2).

At hospital discharge, 153 (18%) children were considered cured of respiratory disease, 624 (73%) had achieved clinical stability, 8 (1%) were deceased, and 71 (8%) gave up treatment and left the hospital due to disease progression or personal reasons. All eight deaths occurred in the pediatric PICU; two of these

---

### TABLE 1  Demographic and clinical characteristics of study subjects

| Characteristic                                      | Cases (n = 334) | Controls (n = 522) | P-value |
|----------------------------------------------------|----------------|-------------------|---------|
| Median age in months (IQR)                         | 6 (2-16)       | 6 (3-19)          | .336    |
| Age in months                                      |                |                   |         |
| 1 mo                                               | 62 (19)        | 62 (12)           |         |
| 2-5 mo                                             | 100 (30)       | 189 (36)          |         |
| 6-11 mo                                            | 62 (19)        | 84 (16)           |         |
| 12-23 mo                                           | 45 (13)        | 70 (13)           |         |
| 24-59 mo                                           | 38 (11)        | 61 (12)           |         |
| 60 + mo                                            | 27 (8)         | 56 (11)           |         |
| Male sex                                           | 218 (65)       | 372 (71)          | .069    |
| History of prematurity                             | 27 (8)         | 39 (7)            | .793    |
| Breast-feeding                                     | 70 (21)        | 121 (23)          | .501    |
| History of past respiratory illness                |                |                   |         |
| Pneumonia $> 3$ mo ago                             | 74 (22)        | 101 (19)          | .340    |
| Asthma and other reactive airway diseases          | 6 (2)          | 25 (5)            | .024    |
| Measles, tuberculosis, and other infectious disease| 11 (3)         | 12 (2)            | .393    |
| Comorbid conditions                                |                |                   | <.001   |
| Congenital heart disease                           | 125 (38)       | 41 (8)            | <.001   |
| Cyanotic congenital heart defects*                 | 13 (4)         | 3 (1)             | <.001   |
| Acyanotic congenital heart defects                 | 112 (34)       | 38 (7)            | <.001   |
| Congenital air way or chromosomal anomalies        | 32 (10)        | 34 (7)            | .115    |
| Moderate-to-severe anemia                          | 14 (4)         | 11 (2)            | .096    |
| Chronic lung diseases                              | 2 (1)          | 5 (1)             | .711    |
| Malnutrition                                       | 2 (1)          | 2 (0)             | .646    |
| Influenza vaccination last year                    | 46 (14)        | 75 (14)           | .841    |
| Ongoing antibiotic treatment                       | 312 (93)       | 516 (99)          | <.001   |

Note: Data are presented as no. (%) of patients unless otherwise indicated.

Abbreviation: IQR, interquartile range.

*Congenital heart disease (defined as International Classification of Diseases, Ninth Revision, codes 745.xx, 746.xx, or 747.xx) was diagnosed at hospital admission, and cyanotic congenital heart defects included Fallot’s tetralogy (ICD-9 code 745.2), transposition of the great arteries (ICD-9 code 745.1x), or tricuspid atresia (ICD-9 code 746.1).
### TABLE 2  Frequency of tested respiratory viruses in cases and controls

| Respiratory viruses | Case (n = 334) | Control (n = 522) | Unadjusted ORs (95% CI) | Adjusted ORs (95% CI) |
|---------------------|---------------|------------------|-------------------------|----------------------|
| Influenza virus     | 28 (8)        | 31 (6)           | 1.59 (0.89-2.84)        |                      |
| A                   | 23 (7)        | 19 (4)           | 2.55 (1.24-5.24)        | 2.52 (1.15-5.55)     |
| B                   | 5 (2)         | 12 (2)           | 0.57 (0.19-1.68)        |                      |
| C                   | 0 (0)         | 0 (0)            | -                       |                      |
| Human rhinovirus    | 78 (23)       | 121 (23)         | 0.98 (0.69-1.39)        |                      |
| Parainfluenza virus | 56 (17)       | 97 (19)          | 0.86 (0.59-1.26)        |                      |
| Type-1              | 15 (5)        | 14 (3)           | 1.54 (0.73-3.22)        |                      |
| Type-2              | 3 (1)         | 6 (1)            | 0.62 (0.15-2.51)        |                      |
| Type-3              | 38 (11)       | 69 (13)          | 0.85 (0.54-1.33)        |                      |
| Type-4              | 5 (2)         | 13 (2)           | 0.56 (0.19-1.62)        |                      |
| Enterovirus         | 9 (3)         | 11 (2)           | 1.51 (0.60-3.76)        |                      |
| Human adenovirus    | 24 (7)        | 46 (9)           | 0.81 (0.46-1.41)        |                      |
| Human coronavirus   | 14 (4)        | 18 (3)           | 1.24 (0.59-2.57)        |                      |
| NL63                | 5 (2)         | 1 (0)            | 6.53 (0.75-56.92)       |                      |
| 229E                | 0 (0)         | 1 (0)            | -                       |                      |
| OC43                | 3 (1)         | 8 (2)            | 0.65 (0.17-2.48)        |                      |
| HKU1                | 3 (1)         | 4 (1)            | 1.11 (0.24-5.05)        |                      |
| Respiratory syncytial virus | 127 (38) | 239 (46) | 0.68 (0.48-0.94) | 0.75 (0.51-1.10) |
| Subgroup A          | 109 (33)      | 199 (38)         | 0.72 (0.51-1.03)        |                      |
| Subgroup B          | 18 (5)        | 41 (8)           | 0.71 (0.39-1.27)        |                      |
| Human metapneumovirus | 14 (4)    | 24 (5)           | 0.93 (0.45-1.95)        |                      |
| Human bocavirus     | 37 (11)       | 45 (9)           | 1.34 (0.83-2.17)        |                      |
| Positive any virus  | 257 (77)      | 409 (78)         | 0.94 (0.65-1.37)        |                      |
| Single detected virus | 160 (48)    | 234 (45)         | 1.16 (0.87-1.54)        |                      |
| Multiple detected viruses | 97 (29) | 175 (34) | 0.80 (0.58-1.10) |                      |
| Two pathogens       | 70 (21)       | 134 (26)         | 0.76 (0.55-1.07)        |                      |
| Three pathogens     | 22 (7)        | 33 (6)           | 1.06 (0.59-1.89)        |                      |
| ≥Four pathogens     | 5 (1)         | 8 (2)            | 0.94 (0.65-1.37)        |                      |

Note: Data are presented as no. (%) of patients unless otherwise indicated.

**FIGURE 2**  Frequency of respiratory viruses detected in cases and controls. Abbreviations: Adv, human adenovirus; EV, enterovirus; HBoV, human bocavirus; HCoV, human coronavirus; HMPV, human metapneumovirus; HRV, human rhinovirus; IFV, influenza virus; PIV, human parainfluenza virus; RSV, respiratory syncytial virus.
At the community level, a majority of episodes of pneumonia in children are caused by respiratory viruses, with RSV (~29% of all pneumonia) and IFV (17%) being the most common viral causes. In contrast, 56%-78% of severe pneumonia is associated with respiratory viruses at the severe pneumonia level, and RSV is considered contributing decreasing to 23% (range: 18%-34%) and IFVs to 7%.[1,3,12,14] At the third level, child deaths caused by viral pathogens are low among children with pneumonia, with only 6.6% of deaths being attributed to RSV and IFVs.[17] It is well-known that most mild-to-moderate childhood pneumonia is caused by viruses, whereas most severe and fatal pneumonia cases are caused by bacterial infections.[3,17] Although the prevalence of RSV is high in hospitalized children in previous study, deaths associated with RSV are uncommon in high-resource settings, and the majority of these deaths occur in children with chronic conditions.[18,19]

In this study, we investigated whether several viral agents are associated with life-threatening events in hospitalized patients with pneumonia using a case-control study. We found that more than 80% of enrolled hospitalized patients tested positive for respiratory viruses. As expected, RSV was the most frequently observed virus,[3,13] but RSV showed no association with life-threatening events in our study. RSV is a major cause of deaths among children with lower respiratory tract illnesses living in low-income to low-middle-income countries, responsible for ~60,000 deaths annually in developing countries in 2015.[20]

The gross regional product per capita in Beijing in 2015 was 106,497 Chinese Yuan ($17,098),[21] which belongs to the high-income regions but not that of low-income to low-middle-income regions according to the World Bank’s classification of economies (gross national income per capita ≥ $12,376). After adjusting for confounding factors, IFV-A was the only viral agent associated with life-threatening pneumonia in children requiring hospitalization, and it was associated with a two-fold increase in life-threatening events. Although IFV-A was identified less frequently in hospitalized patients, 36% of IFV-A-positive inpatients received invasive ventilation and 45% progressed to acute respiratory failure. These results suggest that IFV-A is an important etiological pathogen in the context of pediatric critical care. IFV infection has previously been reported to be associated with an increased risk of cardiac events in adults and with adverse outcomes (eg, shock, neurological disease, organ failures, and death) in children.[22,24] Current clinical guidelines for the management of childhood pneumonia strongly recommend rapid tests for IFV in an inpatient setting.[8,25,26] Our results further emphasize the critical role of IFV-A infections in severe pneumonia in hospitalized pediatric patients. Early pathogen diagnostics and timely antiviral therapies would improve mortality.[25,26]

We also analyzed the relationships between several host factors and life-threatening events. In our study, almost half of children who had life-threatening pneumonia or who were admitted into the PICU were younger than 6 months of age, and 47% had a pre-existing comorbid condition at the time of hospital admission. Congenital heart disease was the most common

---

**TABLE 3** Comparison of clinical characteristics in children suffered from pneumonia with Influenza A virus positive or negative detections

| Characteristic                  | Positive (n = 42) | Negative (n = 814) | P-value |
|---------------------------------|-------------------|--------------------|---------|
| **Clinical signs**              |                   |                    |         |
| Leukocytosis                    | 23 (55)           | 389 (48)           | .430    |
| Leukopenia                      | 2 (5)             | 22 (3)             | .331    |
| Fever (body temperature >38.0°C)| 32 (76)           | 471 (58)           | .023    |
| Hypothermia (body temperature <35.5°C) | 0 (0) | 5 (1) | 1       |
| Tachypnea                       | 14 (33)           | 175 (21)           | .085    |
| Tachycardia                     | 25 (60)           | 334 (41)           | .024    |
| Chest indrawing                 | 21 (50)           | 345 (42)           | .341    |
| Persistent vomiting             | 3 (7)             | 37 (5)             | .440    |
| **Treatment**                   |                   |                    |         |
| Antibiotics                     | 42 (100)          | 786 (97)           | <.001   |
| Anti-virals                     | 10 (24)           | 204 (25)           | 1       |
| Bronchodilators                 | 8 (19)            | 83 (10)            | .075    |
| Steroids                        | 38 (90)           | 650 (80)           | .110    |
| **Clinical outcomes**           |                   |                    |         |
| LoS, median days, (IQR)         | 13 (9-17)         | 11 (8-16)          | .271    |
| Admission to pediatric ICU      | 23 (55)           | 311 (38)           | .036    |
| Transferred immediately to pediatric ICU upon admission | 18 (43) | 259 (32) | .1749 |
| Mechanical ventilation          | 23 (55)           | 298 (37)           | .022    |
| Invasive ventilation            | 15 (36)           | 81 (10)            | <.001   |
| Tracheostomy                    | 5 (12)            | 21 (3)             | .007    |
| Endotracheal tube               | 14 (33)           | 74 (9)             | <.001   |
| Non-invasive, for example, CPAP | 18 (43)           | 275 (34)           | .245    |
| Respiratory failure             | 19 (45)           | 232 (29)           | .024    |
| Shock                           | 1 (2)             | 13 (2)             | .508    |
| Sepsis                          | 1 (2)             | 31 (4)             | 1       |
| Death                           | 0 (0)             | 8 (1)              | 1       |

Note: Data are presented as no. and (%) of patients unless otherwise indicated.

Abbreviations: CPAP, continuous positive airway pressure; ICU, intensive care unit; IQR, interquartile range; LoS, length of hospital stay.

4 | DISCUSSION

Pediatric patients suffering from pneumonia are disproportionately affected by etiologies at different stage of disease development.[1,11]
comorbidity in children with life-threatening pneumonia in critical care (38%), associated with a 10-fold increase in life-threatening events, regardless of viral infections. Young age and congenital heart disease have previously been reported as risk factors for PICU admission using cohorts suffering from severe pneumonia. In Hall et al’s study on children with acute respiratory infections, young age and prematurity were risk factors for hospitalization with RSV infection. Our results showed that young age and congenital heart disease were independent host factors that predispose children to life-threatening pneumonia. Patients with such host factors on admission should be evaluated promptly and carefully to help improve survival, because delayed admission of patients with severe pneumonia to the PICU is associated with higher mortality as previously reported. The influenza vaccination status of children was not associated with life-threatening pneumonia in our study. Because the number of children with influenza A virus (n = 42, 5%) was low in our study, the sample size may be underpowered to conclude the effect of vaccination on influenza virus-associated pneumonia. As we performed a case-control study, this may lead to our samples less representative of the general population. As about 80% of enrolled patients are <2 years old, asthma and chronic lung disease which are more common in elder children were not often in our study. Cystic fibrosis is also rare in China.

The purpose of this study was to investigate viral etiologies predicting the death or survival of patients with severe pneumonia during hospitalization to optimize site of care. There were only eight recorded cases that resulted in a death during the 8-year study period, which limits a further analysis. Although an early termination of treatment may indicate an adverse outcome, these patients were not followed up to determine the ultimate clinical outcomes. Instead, we studied life-threatening events that occurred during hospitalization, including PICU admission, mechanical ventilation, sepsis, shock, and death. In the study, 8% of hospitalized children with pneumonia were transferred to the PICU and experienced at least one the life-threatening event. The observed proportion of pneumonia patients transferred to the PICU is similar to previous reports studying patients in China but is lower than studies conducted in high-income countries (eg, 21% in the USA), suggesting that the burden, severity, and risk factors of childhood pneumonia are potentially different between countries. Policy makers and pediatricians using data from different countries should take into account of these results when optimizing local clinical management strategies and public health policies.

Although our study was conducted in one local children’s hospital, however, the results acquired in the study may be generalizable to children living in the other parts of the nation as the prevalence of viruses tested in our study was quite similar to that of other previous studies, confirming the validity of our results. Further multicenter and prospective studies on the association between IFV-A and life-threatening pneumonia in children are warranted.

5 CONCLUSIONS

This study enriched our understandings on the role of respiratory viruses and host factors in the pneumonia progression of life-threatening events during hospitalization. Respiratory viruses are a large etiological burden among hospitalized children suffering from pneumonia in China, with RSV being the most common viral agent in children in critical care. The presence of IFV-A virus is associated with a two-fold increase in life-threatening events in pneumonia patients. Rapid etiological diagnostics on admission and specific antiviral therapy will be critical for patients receiving critical care. The prevention of IFV-A virus is recommended in children to reduce the risk of life-threatening events.

ACKNOWLEDGEMENTS

We are thankful to the clinicians and other medical staff that helped collect the samples and clinical data. This study is supported by the National Major Science & Technology Project for the Control and Prevention of Major Infectious Diseases in China (2017ZX10103004), by the CAMS Innovation Fund for Medical Sciences [2016-I2M-1-014], and by the Peking Union Medical College Postdoctoral Fund.

AUTHOR CONTRIBUTIONS

Jianxing Yu: Formal analysis (Lead); Funding acquisition (Supporting); Writing-original draft (Equal); Suyun Qian: Data cura-
tion (Equal); Investigation (Lead); Resources (Equal); Chunyan Liu: Investigation (Equal); Validation (Equal); Yan Xiao: Investigation (Equal); Project administration (Equal); Resources (Equal); Teng Xu: Software (Equal); Visualization (Equal); Ying Wang: Data cura-
tion (Equal); Investigation (Equal); Validation (Equal); Hang Su: Resources (Equal); Writing-review & editing (Equal); Lan Chen: Investigation (Equal); Project administration (Equal); Validation (Equal); Bin Yuan: Software (Equal); Writing-review & editing (Equal); Xinning Wang: Investigation (Equal); Project administra-
tion (Equal); Validation (Equal); Baoping Xu: Data curation (Equal); Investigation (Equal); Validation (Equal); Yan Yang: Data curation (Equal); Investigation (Equal); Resources (Equal); Kunling Shen: Supervision (Equal); Zhengde Xie: Conceptualization (Equal); Methodology (Equal); Supervision (Equal); Writing-review & editing (Equal); Lili Ren: Conceptualization (Equal); Funding acquisition (Equal); Project administration (Lead); Supervision (Lead); Writing-review & editing (Equal); Jianwei Wang: Conceptualization (Lead); Funding acquisition (Lead); Methodology (Equal).

ORCID

Jianxing Yu https://orcid.org/0000-0002-9696-2460
Lili Ren https://orcid.org/0000-0002-6645-8183

REFERENCES

1. Rudan I, O’Brien KL, Nair H, et al. Epidemiology and etiology of childhood pneumonia in 2010: estimates of incidence, severe
morbidity, mortality, underlying risk factors and causative pathogens for 192 countries. J Glob Health. 2013;3(1):010401.

2. Walker CL, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405-1416.

3. Jain S, Williams DJ, Arnold SR, et al. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med. 2015;372(9):835-845.

4. Le Roux DM, Myer L, Nicol MP, Zar HJ. Incidence and severity of respiratory viruses in adults with acute respiratory tract infections in Beijing, 2005–2007. Clin Microbiol Infect. 2009;15(12):1146-1153.

5. Levine OS, O'Brien KL, Deloria-Knoll M, et al. The pneumonia etiology research for child health project: a 21st century childhood pneumonia etiology study. Clin Infect Dis. 2012;54(Suppl 2):S93-S101.

6. Principi N, Esposito S. Management of severe community-acquired pneumonia of children in developing and developed countries. Thorax. 2011;66(9):815-822.

7. Benet T, Sanchez Picot V, Messaoudi M, et al. Microorganisms associated with pneumonia in children <5 years of age in developing and emerging countries: the GABRIEL pneumonia multicenter, prospective, case-control study. Clin Infect Dis. 2017;65(4):604-612.

8. Berkley JA, Munywoki P, Ngama M, et al. Viral etiology of severe pneumonia among Kenyan infants and children. JAMA. 2010;303(20):2051-2057.

9. Zhang Q, Guo Z, Bai Z, MacDonald NE. A 4 year prospective study to determine risk factors for severe community acquired pneumonia in children in southern China. Pediatr Pulmonol. 2013;48(4):390-397.

10. Core R, Team R. A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.

11. Wallwork CL, Rudan I, Liu L, et al. Global burden of childhood pneumonia and diarrhoea. Lancet. 2013;381(9875):1405-1416.

12. Benet T, Sanchez Picot V, Messaoudi M, et al. Microorganisms associated with community-acquired pneumonia in children: matched case-control study. Thorax. 2015;70(9):847-853.

13. Shi T, McLean K, Campbell H, Nair H. Aetiological role of common respiratory viruses in acute lower respiratory infections in children under five years: a systematic review and meta-analysis. J Glob Health. 2015;5(1):010408.

14. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946-958.

15. Levine OS, O'Brien KL, Deloria-Knoll M, et al. The pneumonia etiology research for child health project: a 21st century childhood pneumonia etiology study. Clin Infect Dis. 2012;54(Suppl 2):S93-S101.

16. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588-598.

17. Collaborators GL. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the global burden of disease study 2015. Lancet Infect Dis. 2017;17(11):1133-1161.

18. Byington CL, Wilkes J, Korgenski K, Sheng X. Respiratory syncytial virus-associated mortality in hospitalized infants and young children. Pediatrics. 2015;135(1):e24-31.

19. Griffiths C, Drews SJ, Marchant DJ. Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. Clin Microbiol Rev. 2017;30(1):277-319.

20. Shi T, McAllister DA, O'Brien KL, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. Lancet. 2017;390(10098):946-958.

21. National Bureau of Statistics of China. Gross Regional Product (GRP) per capita by province, 2007-2015. 2019; http://data.stats.gov.cn/easyquery.htm?cn=E0103. Accessed October 21, 2019.

22. The World Bank. World Bank Country and Lending Groups: country classification. 2018: https://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups. Accessed October 21, 2019.

23. Kwon JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018;378(4):345-353.

24. Lister P, Reynolds F, Parslow R, et al. Swine-origin influenza virus H1N1, seasonal influenza virus, and critical illness in children. Lancet. 2009;374(9690):605-607.

25. Bradley JS, Byington CL, Shah SS, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America. Clin Infect Dis. 2011;53(7):e25-76.

26. Harris M, Clark J, Coote N, et al. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011;66(Suppl 2):ii1-ii23.

27. Restrepo MI, Mortensen EM, Rello J, Brody J, Anzueto A. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest. 2010;137(3):552-557.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section.

How to cite this article: Yu J, Qian S, Liu C, et al. Viral etiology of life-threatening pediatric pneumonia: A matched case-control study. Influenza Other Respi Viruses. 2020;14:452–459. https://doi.org/10.1111/irv.12738